Mycoplasma testing market expected to value nearly $2 million by 2031 Technology innova
20 March 2024
Technology innovations and a stronger focus on developing novel drugs to treat chronic diseases, are key drivers for the global mycoplasma testing market up to the next decade, research states. According to research published by Coherent Market Insights, the global mycoplasma testing market is anticipated to reach $1,907.6 million by 2031.
By 2030, 150 new chemical enterprises will be created in Russia
20 March 2024
The Minister of Industry and Trade of the Russian Federation, Denis Manturov, announced during a meeting with President Vladimir Putin and members of the Cabinet of Ministers that approximately 150 new medium- and low-tonnage chemical enterprises will be established in Russia by 2030. Manturov stressed that, following the president’s orders, the development of the most crucial sectors for the economy is being shifted to the framework of national projects.
Innovative method could offer cost-effective sterilisation approach
19 March 2024
The new sterilisation method could provide an affordable, rapid approach for preparing microbiological culture media, research suggests.
In 2023, Russia has registered 540 drugs
19 March 2024
In 2023, the Russian Ministry of Health registered a total of 540 medicines, with less than half, specifically 160 (29.6%), being of foreign origin. This was stated by the head of the department, Mikhail Murashko, emphasizing that “Russian pharma has begun to create innovative products.”
Rapid pseudomonas aeruginosa detection method developed
18 March 2024
Research suggests the rapid detection method “will enable the timely implementation of microbiological monitoring strategies for large batches of medications”.
Health Ministry has approved a drug for the treatment of Niemann–Pick disease
18 March 2024
The Ministry of Health of the Russian Federation issued a regulatory certificate to the Dutch company Genzyme Europe (Genzyme has been owned by Sanofi since 2011) for the drug Zenpozyme (olipudase alfa), intended for the treatment of a rare genetic disease – Niemann-Pick disease A/B and B types. In 2023, this disease was included in the roster of conditions entitling individuals to receive treatment funded by the “Circle of Kindness” state fund.
Positive study results in 298 patients with obstructive sleep apnea (OSA)
15 March 2024
Desitin, an expert in neurological and psychiatric therapeutics, reports positive study results from the FLOW study with 298 patients: Nocturnal breathing pauses in patients with obstructive sleep apnea (OSA) were significantly reduced, thus meeting the primary endpoint of the study. With these positive results, a reliable basis for the final clinical phase 3 development of the first oral treatment for OSA has been established. While OSA has serious health implications, only around a third of all patients use the gold standard therapy of Continuous Positive Airway Pressure (CPAP) long-term.
Rapid pseudomonas aeruginosa detection method developed
15 March 2024
Research suggests the rapid detection method “will enable the timely implementation of microbiological monitoring strategies for large batches of medications”. Findings from an experimental study report the development of a rapid method for the detection of pseudomonas aeruginosa bacteria in medications.
Developing new treatment regimens for HIV
14 March 2024
Since the HIV epidemic began in the early 1980s, more than 85 million people have been diagnosed worldwide and about 40 million have died as a result of complications from the virus.1 Now, four decades later, 39 million people around the world are living with HIV, primarily due to advances in treatment.1 With continued innovation on the horizon in terms of prevention and treatment methods, what was once a wishful hope of ending the epidemic has become a conceivable goal.
Life sci marketing budgets boomed in 2023, led by spending on trade shows and websites, survey finds
14 March 2024
Marketing cut a bigger slice of the budgetary pie at life sciences companies in 2023, a recent survey has found. After several COVID-inflected years that saw companies allotting smaller percentages of their total revenues to marketing, 2023 ushered in a return nearly to pre-pandemic levels.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024